Marty Makary, the Commissioner of the U.S.Food and Drug Administration, has resigned after a period of internal turmoil within the agency.His departure comes after White House staff approved a plan to replace him, signaling a shift in leadership priorities.

The changes at the FDA are part of a broader shake-up at the Department of Health and Human Services, where some officials appointed by Health Secretary Robert F.Kennedy Jr.are being replaced with individuals who have more traditional experience in regulatory and health roles.

Kyle Diamantas, who recently oversaw the FDA’s food program and was promoted to a senior counselor role under Secretary Kennedy, has been named the acting leader of the agency.President Donald Trump announced Diamantas’s temporary appointment on his Truth Social platform.

The resignation and leadership changes highlight ongoing tensions and differing approaches within the federal health administration, as officials seek to balance innovation with regulatory oversight and restore stability within the FDA.

Makary’s exit marks one of the most notable leadership changes in the current administration, reflecting broader political and administrative pressures affecting federal health agencies.